Kim JW, et al. Korean J Radiol. 2020 Jul;21:e118. https://doi.org/10.3348/kjr.2020.0067

Bae IE, et al. J Korean Surg Soc. 2012 Dec;83(6):381-387. http://dx.doi.org/10.4174/jkss.2012.83.6.381

Cho NR, et al. Yonsei Med J. 2021 Dec;62(12):1098-1106. https://doi.org/10.3349/ymj.2021.62.12.1098

Ahram Han, M.D., Jihun Gwak, M.D., Gangkook Choi, M.D., Jae Jeong Park, M.D., Byungchul Yu, M.D., Gil Jae Lee, M.D., Jin Mo Kang, M.D.. Journal of Trauma and Injury 2017;30:220-6. https://doi.org/10.20408/jti.2017.30.4.220

A recent meta-analysis addressed increased risk of death following revascularization with paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause mortality and amputation free survival between peripheral arterial disease (PAD) patients who were treated with paclitaxel-coated devices and non-paclitaxel-coated devices. This was retrospective population-based cohort study from the National Health Insurance Service claims in South Korea from 2015 to 2019. Multivariate Cox regression analyses after propensity score matching were applied to identify all-cause mortality and amputation-free survival. After propensity score matching, there were 6090 patients per group. The median follow-up days was 580 days (interquartile range [IQR] 240–991 days) and 433 days (IQR 175–757 days) for the non-paclitaxel-coated device group and paclitaxel-coated device group, respectively. Multivariate analysis adjusted for age, sex, diabetes, hypertension, warfarin, and new oral anticoagulants showed that the mortality rate associated with paclitaxel-coated devices was not significantly higher than non-paclitaxel-coated devices (hazard ratio [HR] 0.992; 95% CI 0.91–1.08). The rate of amputation events was higher in patients with paclitaxel-coated devices than those with non-paclitaxel-coated devices (HR 1.614; 95% CI 1.46–1.78). In this analysis, the mortality rate in patients with PAD was not associated with the use of paclitaxel-coated devices, despite a higher amputation rate.